Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Article |

Calcium Antagonists Coming of Age: Heterogeneous Class Reveals Broad Therapeutic Potential

Beverly Merz
JAMA. 1987;257(10):1283-1284. doi:10.1001/jama.1987.03390100017005.
Text Size: A A A
Published online


CALCIUM ANTAGONISTS are expanding in number, complexity and therapeutic scope. This class of compounds, the first of which were developed as coronary vasodilators, is now being investigated as therapy for disorders ranging from hyperlipidemia to intermittent claudication. And, in the 24 years since the discovery of the first calcium antagonist, the class has grown to include more than 20 therapeutic compounds.

At a recent international symposium sponsored by the New York Academy of Sciences and the Fondazione Giovanni Lorenzini, 250 basic and clinical investigators spent four days in New York City discussing the pharmacology, physiology, and clinical potential of calcium antagonists. What emerged was a picture of a heterogeneous group of agents whose specific indications are just beginning to be defined.

Albert Fleckenstein, PhD, recounted early research with calcium antagonists. Fleckenstein, now professor of physiology, University of Freiberg, West Germany, recalled that he coined the term "calcium antagonist" in 1964


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?




Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.